NCT06217614 is a NA clinical trial of (Manuka honey-green tea) in Xerostomia, sponsored by British University In Egypt.

Who is sponsoring NCT06217614?

NCT06217614 is sponsored by British University In Egypt.

What drugs are being tested in NCT06217614?

Interventions in NCT06217614: (Manuka honey-green tea).

What condition does NCT06217614 study?

NCT06217614 studies Xerostomia, Diabetes Mellitus, Hypertension, Post COVID-19 Condition.

Is NCT06217614 still recruiting?

NCT06217614 is currently completed. Last updated 9 May 2024.

Last reviewed 2024-05-09 · How we verify

NCT06217614

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beneficial Effects of Natural Products on Management of Xerostomia

Completed NA Last updated 9 May 2024

What this trial tests

NA trial testing (Manuka honey-green tea) in Xerostomia in 28 participants. Completed in 1 October 2022.

Timeline

1 August 2022

Primary endpoint
1 September 2022

1 October 2022

Quick facts

Lead sponsor	British University In Egypt
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	28
Start date	1 August 2022
Primary completion	1 September 2022
Estimated completion	1 October 2022
Sites	1 location across Egypt

Drugs / interventions tested

(Manuka honey-green tea)

Conditions studied

Xerostomia — all drugs for Xerostomia →
Diabetes Mellitus — all drugs for Diabetes Mellitus →
Hypertension — all drugs for Hypertension →
Post COVID-19 Condition — all drugs for Post COVID-19 Condition →

Sponsor

British University In Egypt

Who can join

19 and older, any sex, with Xerostomia or Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Xerostomia, the subjective feeling of oral dryness, is a symptom most frequently accompanied by either decreased salivary flow or an altered composition of saliva. Hyposalivation, on the other hand, is the objective measured reduction in salivary flow rate. Xerostomia is a relatively common complaint, particularly among older people, and can lead to major consequences with regard to the quality of their general and oral health and wellbeing. Xerostomia has a variety of possible etiological factors; it is generally classified as having primary and secondary causes. Primary causes comprise conditions that directly affect the salivary glands and induce xerostomia like, Sjogren's syndrome, diabetes mellitus type 1 and 2, thyroid disease, adrenal pathology, renal or hepatic diseases, hepatitis C virus infection, and HIV disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Harnessing Nature's Toolbox: Naturally Derived Bioactive Compounds in Nanotechnology Enhanced Formulations.
Sanjai C, Gaonkar SL, Hakkimane SS. · · 2024 · cited 10× · PMID 39494011 · DOI 10.1021/acsomega.4c07756

Verify or expand the search:

Other recruiting trials for Xerostomia

Currently open trials in the same condition.

NCT07394842 — Longitudinal Oral Health Changes After Head and Neck Radiotherapy · active not recruiting
NCT06465628 — Acupressure on Xerostomia in Head and Neck Cancer Patients · NA · recruiting
NCT06365047 — Dry Mouth Toothpaste Study - Comparing Two Toothpastes With Arginine · Phase 3 · active not recruiting
NCT06194123 — Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis · NA · active not recruiting
NCT06287294 — An Investigation Into Taste Problems Associated With Xerostomia in Patients With Advanced Cancer · recruiting

Other British University In Egypt trials

Trials by the same sponsor.

NCT07492576 — Evaluation of the Magnesium Shield Compared to Dual Zone Grafting Approach in Immediate Implant Site Management · NA · recruiting
NCT07457749 — Clinical Performance of a Novel Self-cured Resin Composite Compared to a Light-cured Bioactive Resin Composite Restorati · EARLY_PHASE1 · recruiting
NCT07368621 — Effectiveness of Connective Tissue Graft With and Without Leukocyte Platelet Rich Fibrin on Peri-implant Soft Tissue Thi · NA · recruiting
NCT07480070 — Two-Year Clinical Performance of Self-Cured Resin Composite in Comparison to Light-Cured Bioactive Resin Composite in Re · NA · completed
NCT07115758 — Vestibular Versus Trapezoid Flap in Immediate Implants · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06217614 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by British University In Egypt
Last refreshed: 9 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06217614.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing